scholarly journals LANGUAGE OF PHARMACEUTICAL ADVERTISING: ONOMASTICS DIMENSION

2020 ◽  
Vol 0 (1(44)) ◽  
pp. 212-219
Author(s):  
С. В. Насакіна
Keyword(s):  
Pharmaceutical Advertising

Research on the Effects of Over-the-Counter Drug Advertising

1974 ◽  
Vol 4 (3) ◽  
pp. 223-226 ◽  
Author(s):  
Donald L. Kanter
Keyword(s):  
Drug Misuse ◽  
Pharmaceutical Advertising ◽  
Drug Usage ◽  
Over The Counter ◽  
Drug Advertising ◽  
The Social ◽  
The Media ◽  
Commercial Advertising ◽  
The Impact

Dr. Kanter presents a summary of his research assessing the role of OTC advertising in Influencing drug usage. His work represents the only systematic study of the impact of commercial advertising on drug usage. He stresses that advertising in itself does not directly lead to drug misuse but should be considered as part of a host of factors in the social environment and in the media environment that have significant influence in determining people's behavior. He also urged that the existing pharmaceutical advertising codes, which are often violated, be reviewed and strengthened.

Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion?

1994 ◽  
Vol 24 (1) ◽  
pp. 91-104 ◽  
Author(s):  
Joel Lexchin
Keyword(s):  
Advisory Board ◽  
Regulatory Body ◽  
Pharmaceutical Advertising ◽  
Government Control ◽  
Promotional Material ◽  
Legislative Authority ◽  
Pharmaceutical Manufacturers ◽  
Pharmaceutical Promotion ◽  
Enforcement Mechanisms ◽  
Prescribing Information

Pharmaceutical promotion in Canada is controlled by two codes: a voluntary one developed by the Pharmaceutical Advertising Advisory Board dealing mostly with printed promotional material, and one from the Pharmaceutical Manufacturers Association of Canada covering other forms of promotion. This article looks at enforcement of the provisions of these codes and at areas in which they are deficient. One of the major weaknesses in both codes is their lack of effective sanctions for companies that violate their provisions. Strong codes are necessary because many physicians rely heavily on promotional material for their source of prescribing information. However, voluntary codes or codes developed by the industry are inherently weak and lack effective enforcement mechanisms. Although the U.S. Food and Drug Administration is currently very active in curtailing promotional excesses, government control is not the solution since regulatory action will depend on the ideological position of the head of the regulatory body and/or the party in power. An independent body backed by legislative authority is preferable.

Ethics of Implicit Persuasion in Pharmaceutical Advertising

2014 ◽  
pp. 1647-1667 ◽  
Author(s):  
Paul Biegler ◽  
Jeanette Kennett ◽  
Justin Oakley ◽  
Patrick Vargas
Keyword(s):  
Pharmaceutical Advertising

scholarly journals Psychiatrists' appreciation of statistical v. clinical significance: a quick test

2009 ◽  
Vol 33 (8) ◽  
pp. 293-295
Author(s):  
Alan Smith ◽  
James Warner
Keyword(s):  
Critical Appraisal ◽  
Response Rate ◽  
Complete Response Rate ◽  
Statistical Significance ◽  
Complete Response ◽  
Study Data ◽  
Clinical Implications ◽  
Pharmaceutical Advertising ◽  
Transferable Skills ◽  
Better Than

Aims and MethodPharmaceutical advertising material can confuse clinical and statistical significance. We used a brief questionnaire (five questions) to evaluate psychiatrists' appreciation of this difference. This approximated to the level of critical appraisal competence of the MRCPsych part 3 examination.ResultsOf the 113 questionnaires distributed 93 were returned complete (response rate 82%). Senior trainees were significantly better than junior trainees at correctly interpreting data (mean score (maximum 5) 2.61v.2.08; P = 0.04). Consultants did less well than senior trainees, although our sample of consultant respondents was too small for significance testing.Clinical ImplicationsLearning critical appraisal for the MRCPsych examination may provide psychiatrists with valuable transferable skills and prevent gaps in our knowledge being exploited by misleading study data. Psychiatrists of all grades need to maintain their research appraisal skills and should not regard the MRCPsych examination as the end of their learning.

scholarly journals The introduction of the medicinal partner in direct-to-consumer advertising: Viagra’s contribution to pharmaceutical fetishism and patient-as-consumer discourse in healthcare

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Janelle Applequist
Keyword(s):  
United States ◽  
Erectile Dysfunction ◽  
Pharmaceutical Industry ◽  
The United States ◽  
Social Meaning ◽  
Pharmaceutical Advertising ◽  
Direct To Consumer ◽  
Look Back ◽  
Market Transaction ◽  
Direct To Consumer Advertising

Pfizer, manufacturer of the erectile dysfunction prescription treatment Viagra, has been a staple in the pharmaceutical advertising arena since broadcast versions of such ads became legally permissible in the United States in 1997. Given that the patent for Viagra is soon set to expire, it is important that research take a look back in an attempt to contextualize the brand’s place in shaping medicinal marketing culture. Of particular interest is the period beginning in 2014, when Viagra’s most unconventional campaign yet began using a tactic that was the first of its kind for the pharmaceutical industry. By removing the actual consumer of the medication from these ads (males), Viagra has paved the way for pharmaceutical advertising to target the medicinal partner. This manuscript reviews the first use of the medicinal partner in the pharmaceutical advertising sector, conducting a textual analysis of Viagra’s use of this mediated relationship. The medicinal partner is the pharmaceutical industry’s attempt to target a patient’s social circle in an effort to promote a discourse that suggests a medicinal remedy for a problem. This analysis describes how social meaning and relationships underlie the market transaction of obtaining a prescription, as has been previously established through the processes of medicalization and pharmaceutical fetishism. These advertisements create belief in the larger sense, meaning Pfizer is infiltrating upon the patient’s process of choice and consumption of medicinal remedies. Viagra is simultaneously encouraging male consumers to celebrate the brand while using female ambassadors to influence the decision to request medicinal intervention.

scholarly journals Stigmatising pharmaceutical advertisements

2000 ◽  
Vol 177 (05) ◽  
pp. 467-468 ◽  
Author(s):  
D. McKay
Keyword(s):  
Mental Disorder ◽  
Health Professionals ◽  
General Public ◽  
The Other ◽  
Pharmaceutical Advertising ◽  
Negative Image

The general public holds stigmatising attitudes toward those with mental disorder, with schizophrenia being rated as highly associated with dangerousness and unpredictability (Crisp et al, 2000). The authors mention that health professionals may share some of these views. After reading their article, I was struck by a number of pharmaceutical advertisements elsewhere in the same issue of the Journal, that appeared to perpetuate a negative image of schizophrenia. My curiosity thus stimulated, I performed a cursory lunchbreak study examining the portrayal of people with mental disorder in pharmaceutical advertising in three recent issues of international psychiatric journals (Table 1). It was notable that all the advertising for antidepressants had positive imagery. Indeed this was also largely true for the ‘other’ category, with only one negatively rated advertisement.

scholarly journals Antidepressant Advertising in China and the UK: The Strengths and Limits of Policy Learning

2019 ◽  
Vol 239 ◽  
pp. 752-774
Author(s):  
Robert Geyer ◽  
Fang Wang
Keyword(s):  
Critical Discourse Analysis ◽  
Prescription Drugs ◽  
Antidepressant Drug ◽  
Critical Discourse ◽  
Policy Learning ◽  
Regulatory Regime ◽  
Pharmaceutical Advertising ◽  
Drug Advertising ◽  
The World ◽  
The Uk

AbstractChina is expected to become one of the largest markets for prescription drugs in the world and pharmaceutical advertising is becoming increasingly important, particularly in the socially and culturally contested area of mental health. This article briefly explores the background of drug advertising policies in China and the UK and focuses on the distinctive challenges of antidepressant drug regulation. Then, using tools of critical discourse analysis, it examines Chinese antidepressant adverts, and compares them with relevant British adverts. The findings indicate that, relative to the UK, Chinese antidepressant adverts are generally oversimplified, and the critical information concerning the concepts of caution, danger and adverse effects are underrepresented. However, there are many interdependent factors that contribute to the distinctive Chinese antidepressant drug regulatory regime. Hence, Chinese policymakers must maintain a delicate balance between learning from Western regulatory regimes, but also avoiding borrowing too heavily from them.

Sign in / Sign up

Export Citation Format

Share Document